【摘 要】
：
Hengruis Discovery and Development Programs on Anti-diabetic Clinical Candidate will be discussed including SP2086 Retagliptin which is in Phase Ⅰ clinical trial in US.
【机 构】
：
Shanghai HengRui Pharmceutical Co.,Ltd China
【出 处】
：
中国上海第七届国际新药发明科技年会
论文部分内容阅读
Hengruis Discovery and Development Programs on Anti-diabetic Clinical Candidate will be discussed including SP2086 Retagliptin which is in Phase Ⅰ clinical trial in US.
其他文献
Background:Drug eluting stents reduce neointima growth and revascularization rates but at the expense of delaying re-endothelialization (RE) of the stented artery and as a result may place patients at
Over 60% of ongoing cell therapy interventions utilize autologous and allogeneic adult stem cells,a large proportion of which are based on mesenchymal stem cells (MSCs).Although a precise definition o
Nearly half of known antibiotics act on the ribosome,an important and enduring antibacterial target.Although its size and complexity have always presented special challenges,X-ray crystallography of r
Classical antibiotics target vital cell functions,but this strategy has led to the development of multi-resistant microbes and we are running out of options to cure such infections.Therefore,novel sol
The glucocorticoid action has been implicated in the development of the Metabolic Syndrome.Systemic glucocorticoid excess induces central obesity,insulin resistance,dyslipidemia and hypertension,the s
Type 2 diabetes is a major health risk in many countries and incidence rates are increasing.Diverse antidiabetic agents are available that act through various mechanisms on different organs.Mechanism-
Compelling animal and human data indicate that stress compromises neurotrophic functions producing neural atrophy and reducing neuroplasticity resulting in dysfunction in brain circuitry associated wi
1.Background Melanin-concentrating hormone (MCH) is a cyclic 19-amino acid neuropeptide that is predominantly expressed in the central nervous system (CNS).It has been demonstrated that MCH plays an i
CRO in India is a recent development,only a decade and half old.The first five years went mostly in capability building and also in trying to gain credibility.During this time the first few pharmaceut
Background:Diabetes Mellitus is a chronic disease prevailing in modem societies.Contributing factors accounted for diabetes include genetic autoimmune dysfunction and excessive intake of energy that l